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Editorial
Rebound stridor in children 
with croup after nebulised 
adrenaline: does it really exist?
Laryngotracheobronchitis is a common childhood 
illness affecting 3% of children. Most of the 
affected children are aged between 6 months 
and 3 years, with a peak incidence of 60 per 1000 
child-years in those children aged between 1 and 
2 years [1]. Epidemiological studies suggest that 
1–5% of children with croup are admitted to 
hospital and 2–3% of those admitted children, 
require intubation [2]. Death is extremely rare and 
has been estimated to occur in no more than 1 
in 30 000 cases [2]. Parainfluenza (types 1 and 3), 
and influenza A and B are the most common viral 
agents causing croup. Respiratory syncytial virus 
(RSV), rhinovirus, coronavirus, metapneumovirus 
and adenovirus are also responsible for this illness. 
There is seasonality to the prevalence with more 
presentations in the autumn. There is an annual 
pattern influenced by the variability of the viruses 
in the community for that year [2].
Croup is characterised by a “barking” cough, 
hoarse voice, stridor and respiratory distress caused 
by generalised airway inflammation and oedema of 
the upper airway mucosa. Most children have mild 
illness which resolves spontaneously without any 
specific treatment. However, some children have 
severe illness with stridor, respiratory distress and 
hypoxaemia requiring intubation. Current evidence 
strongly supports the use of glucocorticoids for the 
management of croup [3]. Previously it was felt that 
steroids took up to 6 h to have an effect on the 
airway [4], but a recent Cochrane review concluded 
that glucocorticoids improve croup symptoms 
at 2 h with the effect lasting at least 24 h [3]. 
Glucocorticoids also reduce rates of return visits, 
admissions and readmissions. When treated with 
placebo, 204 out of every 1000 children will return 
for medical care. When treated with glucocorticoids, 
74–153 out of every 1000 children will return 
for medical care [3]. Glucocorticoids reduce the 
length of stay by 15 h (range 6–24 h), but make 
no difference to the need for additional treatments. 
Dexamethasone 0.15 mg·kg−1 or prednisolone 
1 mg·kg−1 would be the recommended treatment 
dosing [2], although other guidelines suggest doses 
up to 0.6 mg·kg−1 of dexamethasone [3].
Nebulised adrenaline/epinephrine is recom-
mended for use in severe and life-threatening 
croup [5], although some guidelines use it for those 
children with moderate symptoms [6]. Nebulised 
adrenaline has been associated with a clinically and 
statistically significant transient reduction in croup 
symptoms 30 min post-treatment [5] and can “buy 
time” for steroids to act. Children with croup develop 
swelling of inner mucosal layers of the larynx and 
trachea. Nebulised adrenaline is thought to act by 
stimulating α-adrenergic receptors in subglottic 
mucous membranes, producing vasoconstriction 
and decreased mucosal oedema. The clinical effect 
is sustained for at least 1 h, but disappears after 
2 h. Studies of nebulised adrenaline treatment of 
croup have used both racemic and l-adrenaline. 
One small trial found that l-adrenaline (5.0 mL, 
0.1% (1:1000)) was as effective and safe as racemic 
adrenaline (0.5 mL, 2.25%) [7]. When racemic and 
l-adrenaline are compared, there is no difference in 
croup score at 30 m (standardised mean difference 
0.33, 95% CI −0.42–1.08), but at 2 h l-adrenaline 
shows a small reduction in croup score compared 
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with racemic adrenaline (standardised mean dif-
ference 0.87, 95% CI 0.09–1.65) [5].
There is a widespread belief amongst 
clinicians that such treatment can cause rebound 
phenomenon [8]. This was first suggested in 1978 [8] 
and 40 years on, continues to be mentioned as a 
possibility in publications in 2018 [1].
Rebound is defined as a temporary deviation 
from a normal state in the opposite direction 
following an abrupt removal or discontinuation 
of a variable, such as a treatment suddenly 
discontinued after long-term use, a passive 
resistance that is released suddenly, an undershoot 
in an effort to restore balance or homeostasis, or a 
condition wherein the maximum therapeutic effect 
is reached and the opposite effect ensues [9]. 
The rebound phenomenon occurs when the 
sudden discontinuation of a medication results 
in the relapse of symptoms that are worse 
than those before the treatment. Examples of 
rebound phenomenon include Stewart–Holmes 
test for cerebellar lesions [10] and Somogyi 
phenomenon [11].
We hypothesise that children with croup, 
following treatment with nebulised adrenaline may 
develop re-emergence of their initial symptoms, 
which are milder than at initial presentation and 
no worse than at baseline and that rebound of 
symptoms in croup does not occur after treatment 
with nebulised adrenaline. We performed a literature 
search to ascertain the degree of re-emergence 
symptoms and to determine if it were worse than 
baseline. The search was completed independently 
by two authors (M.S. and S.E.).
Search question
Do children with croup (patient group) when 
treated with nebulised adrenaline (intervention) 
develop re-emergence of stridor, worse than 
the initial baseline presentation (comparison) as 
defined by changes in symptoms score (outcome)?
Search strategy
Secondary sources: the Cochrane library was 
searched in September 2018 with the terms Croup 
and Adrenaline OR Epinephrine. One relevant 
review [5] was identified. The review included 
eight studies. Primary sources: MEDLINE was 
searched via PubMed using following terms Croup 
OR Laryngitis AND Adrenaline OR Epinephrine 
OR rebound stridor. Inclusion criteria were that 
studies included children between the ages of 
0 and 18 years. 41 clinical trials were retrieved. 
A further two studies [12, 13] were considered 
relevant, in addition to the eight studies included 
in the Cochrane review. Summaries of the papers 
are presented in the table 1.
Discussion
The management of children with croup has had 
several controversies over the decades. In 1988, 
a review by Couriel [21] emphasised the lack of 
high-quality studies to aid management. Nebulised 
adrenaline was advocated only in children with 
impending airway obstruction, due to the transient 
improvement and possibility of rebound. The 
benefit of steroids in the management was not 
clearly established at that time and hence most 
early studies compared treatments of nebulised 
adrenaline with placebo or racemic adrenaline 
versus l-adrenaline.
Lenny and Milner [8] proposed the possibility 
of rebound phenomenon in children with acute 
viral croup treated with a nebulised α-adrenergic 
stimulant. The authors studied the total airway 
resistance before and after administration of 
nebulised phenylephrine in eight children. Prior to 
nebulisation, two drops of 0.05% xylometazoline 
were instilled in each nostril to ensure full nasal 
patency and children were sedated with 80 mg·kg−1 
chloral hydrate. Seven out of eight children who 
were treated with nebulised phenylephrine 
showed improvement clinically and in terms of 
airway resistance. One child who did not show 
improvement was later was diagnosed with acute 
epiglottitis. The authors reported that improvement 
was transient and the airway resistance returned 
to pre-treatment levels within 30 min, which was 
hypothesised as a possible rebound phenomenon.
Over the following 40 years, the 10 studies 
identified here are very reassuring in that rebound 
does not exist and that although symptoms may 
return after the use of nebulised adrenaline, no 
study has reported the symptoms as being worse 
than baseline. If steroids are used as well then, as 
their effect starts to impact the upper airway at 2 h 
post-administration, this reduces any re-emergence 
of symptoms post-adrenaline as that effect wears 
off after 1–2 h.
A small underpowered study from 1973 by 
Gardner et al. [20], reported before the advent of 
the widespread use of steroids, was a retrospective 
review and this, not surprisingly, failed to 
substantiate a decrease in either hospitalisation or 
symptoms resulting from treatment with nebulised 
adrenaline. They did, however, acknowledge that 
adrenaline may be of therapeutic value in some 
patients with croup depending on the aetiological 
agent but may simply be the addition of moisture 
to the airways.
Three small studies [17–19], involving 48 children 
in total, showed significant initial improvement 
using nebulised adrenaline compared to placebo 
with some return of symptoms but no rebound 
reported. The following studies started using steroids 
in their design and recruited larger numbers but 
in children with more severe croup. No rebound 
of symptoms is described and an effect of the 
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steroids reducing any re-emergence of symptoms is 
becoming clearer [7, 15, 16] (see table 1).
Kristjansson et al. [14] reported re-emergence 
of symptoms in 35% of children receiving nebulised 
adrenaline and in 25% of children receiving 
placebo. No steroids were used. They posited that 
it is not likely that the phenomenon is related to 
adrenaline only, but rather to ongoing inflammation 
and oedema in the airway. They concluded that 
nebulised adrenaline is effective for the treatment 
of acute mild to moderately severe croup and that 
it should be used as a first line treatment [14]. 
This has not been taken up universally, but it is 
now standard practice in some countries to use 
steroids and nebulised adrenaline in the emergency 
department, watch the patients for 2 h and then 
discharge home if well enough [2]. The final two 
studies both used steroids and nebulised adrenaline, 
showing clearly a good response to the treatment 
with no rebound or indeed any major re-emergence 
of symptoms [12, 13].
The data presented here are reassuring in 
that re-emergence of symptoms may occur but 
is no worse than baseline. The re-emergence of 
symptoms is less marked in studies when children 
received concurrent steroids.
So, in answer to the proposed question: “Do 
children with croup (patient group) when treated 
with nebulised adrenaline (intervention) develop 
re-emergence of stridor, worse than initial baseline 
presentation (comparison) as defined by changes in 
symptoms score (outcome)?” Or “Rebound stridor 
in children with croup after nebulised adrenaline: 
does it really exist?” The answer is no.
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